Search Results
Search results for "Beth Fleck"
Results found for "Beth Fleck"
Posts (184)
- Job Opportunity Spotlight #1: Principal Scientist, In Vitro Pharmacology
As Chief Matchmaker, I recently had the pleasure of speaking with Beth Fleck, Director of In Vitro Pharmacology Mark: “Beth, why did you decide to join Crinetics?” Beth: “Yes. There are a lot of learning opportunities at Crinetics. Mark: “Beth, why would someone want you as their boss?” Beth: “Well, I enjoy training and mentoring team members.Â
- đź“° GPCR Weekly News, May 20 to 26, 2024
Mark recently discussed this exciting opportunity with Beth Fleck, Director of In Vitro Pharmacology
- đź“° GPCR Weekly News, April 22 to 28, 2024
Our Chief Matchmaker, Mark Schmeizl, had a great conversation about this position with Beth Fleck, Director
Other Pages (32)
- Sam Hoare: Receptor Residence Time and GPCR Data Analysis | Dr. GPCR Ecosystem
But when Beth Fleck measured dissociation rates of the CRF receptor radioligands, the compound that worked
- Fiona Marshall: Three Decades Inside GPCR Drug Discovery | Dr. GPCR Ecosystem
Marshall, the throughline is personal: she remembers the exact lecture at Bath where she first heard The moment baclofen activated ion channels in Xenopus oocytes expressing both — with Dr. mic Selected Quotes "We did the classic experiment in Xenopus oocytes, where you inject the cDNA of both About this episode Fiona Marshall got fascinated with GPCRs after attending a lecture on how the beta-adrenergic receptor in the heart is activated by adrenaline, during her undergraduate studies at Bath University
- Robert J. Lefkowitz: Beta-Adrenergic Receptors, the GPCR Family, and Fifty Years of Discovery | Dr. GPCR Ecosystem
traces the accidental origins of his receptor research — from a Vietnam War draft to the cloning of the beta Lefkowitz: Beta-Adrenergic Receptors, the GPCR Family, and Fifty Years of Discovery The existence of Using radioligand binding assays developed for the beta-adrenergic receptor system, his lab purified, The same system yielded the discovery of beta-adrenergic receptor kinase (now GRK2) and the beta-arrestins The strategic logic behind choosing beta-adrenergic receptors The selection of the beta-adrenergic system




